$10.80
0.31% yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US23306J1016
Symbol
DBVT
Sector
Industry

DBV Technologies SA Sponsored ADR Stock price

$10.80
+2.08 23.85% 1M
+5.39 99.63% 6M
+7.71 249.51% YTD
+6.84 172.52% 1Y
-13.10 54.81% 3Y
-31.10 74.22% 5Y
-357.70 97.07% 10Y
-218.20 95.28% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.03 0.31%
ISIN
US23306J1016
Symbol
DBVT
Sector
Industry

Key metrics

Basic
Market capitalization
$304.9m
Enterprise Value
$279.4m
Net debt
positive
Cash
$32.5m
Shares outstanding
102.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
73.5 | 4.1
EV/Sales
67.3 | 3.7
EV/FCF
negative
P/B
11.1
Financial Health
Equity Ratio
41.8%
Return on Equity
-416.7%
ROCE
-338.6%
ROIC
-1,156.1%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$4.2m | $74.7m
EBITDA
$-111.7m | $-147.9m
EBIT
$-116.5m | $-196.1m
Net Income
$-114.1m | $-112.4m
Free Cash Flow
$-105.5m
Growth (TTM | estimate)
Revenue
-73.6% | 1,701.0%
EBITDA
-28.2% | -27.6%
EBIT
-52.7% | -68.4%
Net Income
-57.0% | 1.5%
Free Cash Flow
-34.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,690.1% | -197.9%
EBIT
-2,806.0%
Net
-2,749.3% | -150.4%
Free Cash Flow
-2,542.1%
More
EPS
$-1.2
FCF per Share
$-1.0
Short interest
0.1%
Employees
110
Rev per Employee
$40.0k
Show more

Is DBV Technologies SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

DBV Technologies SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:

6x Buy
75%
1x Hold
13%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a DBV Technologies SA Sponsored ADR forecast:

Buy
75%
Hold
13%
Sell
13%

Financial data from DBV Technologies SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4.15 4.15
74% 74%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
1% 1%
738%
- Research and Development Expense 89 89
24% 24%
2,141%
-112 -112
28% 28%
-2,691%
- Depreciation and Amortization 4.81 4.81
145% 145%
116%
EBIT (Operating Income) EBIT -116 -116
53% 53%
-2,807%
Net Profit -114 -114
57% 57%
-2,750%

In millions USD.

Don't miss a Thing! We will send you all news about DBV Technologies SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DBV Technologies SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
17 days ago
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Alle...
Neutral
GlobeNewsWire
30 days ago
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United...
Neutral
GlobeNewsWire
about one month ago
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired ...
More DBV Technologies SA Sponsored ADR News

Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Head office France
CEO Daniel Tassé
Employees 110
Founded 2002
Website www.dbv-technologies.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today